Desipramine for Major Depressive Disorder
Start desipramine at 25 mg at bedtime in adults, increase by 25 mg every 3-7 days as tolerated, targeting 100-200 mg daily with a maximum of 150 mg daily (or up to 300 mg in hospitalized patients under close supervision). 1
Starting Dose
- Adults (outpatients): 25 mg at bedtime 2, 3
- Elderly/Adolescents: 10-25 mg in the morning 3, 1
- Lower starting doses are mandatory for elderly patients and outpatients compared to hospitalized patients 1
Titration Schedule
Increase by 25 mg daily every 3-7 days as tolerated 2. The titration should be guided by:
- Clinical response
- Tolerability (especially drowsiness, dizziness, postural hypotension)
- ECG monitoring if doses approach 100 mg or higher 2
Maximum Dose
- Outpatients: 150 mg daily 3, 1
- Hospitalized patients (under close supervision): Up to 300 mg daily 1
- Elderly/Adolescents: Maximum 100 mg daily (up to 150 mg in severe cases, but >150 mg not recommended) 3, 1
Critical safety note: Doses above 300 mg are never recommended 1. If blood concentration of active medication plus metabolite is <100 ng/mL, continue titration with caution beyond 150 mg 2.
Therapeutic Drug Monitoring
Target therapeutic plasma level: ≥115-125 ng/mL 4. Research demonstrates that 89% of patients with levels >115 ng/mL responded versus only 14% below this threshold 4. Blood level monitoring is particularly helpful when:
- Inadequate response despite adequate dosing
- Suspected noncompliance
- Drug interactions present
- Elderly patients (>65 years) 5
- Genetic polymorphisms affecting metabolism 5
Duration of Adequate Trial
6-8 weeks total, including at least 2 weeks at maximum tolerated dosage 2. This extended trial period is necessary because tricyclic antidepressants require time to reach steady-state and demonstrate full therapeutic effect.
Contraindications
Absolute Contraindications:
- Concurrent MAOI use (or within 14 days of discontinuation) 1
- Acute recovery phase post-MI 1
- Seizure disorders or conditions lowering seizure threshold (stroke, brain metastases) 3, 6
- Closed-angle glaucoma 3
Relative Contraindications/Cautions:
- Cardiac disease: Ischemic heart disease or ventricular conduction abnormalities require caution, limit to <100 mg daily when possible 2
- Age >40 years: Obtain screening ECG before initiation 2
- Concurrent tamoxifen use 3
- Premature ventricular contractions 3
Monitoring Parameters
Baseline:
- ECG (mandatory if age >40 or any cardiac history) 2
- Comprehensive psychiatric assessment including suicide risk 1
- Screen for bipolar disorder (detailed psychiatric and family history) 1
- Blood pressure (orthostatic measurements)
Ongoing Monitoring:
- Weekly visits initially (first 1-2 weeks) to assess suicidality, agitation, unusual behavioral changes 7, 1
- ECG monitoring: Watch for QRS or QT prolongation (best early indicator of toxicity at high doses) 1. PR interval prolongation is also significant 1
- Blood pressure: Monitor for orthostatic hypotension, especially in elderly 1
- Clinical symptoms: Drowsiness, dizziness, tachycardia 3, 1
- Therapeutic drug levels: Consider at 2-4 weeks if inadequate response or tolerability concerns 5, 4
Specific Adverse Effects to Monitor:
- Serotonin syndrome if combined with other serotonergic agents (mental status changes, autonomic instability, neuromuscular changes) 1
- Anticholinergic effects: Though desipramine has lower risk than tertiary amines, still monitor for dry mouth, constipation, urinary retention 3
- Cardiac toxicity: Tachycardia, conduction delays 3
Dosing Schedule
Once-daily dosing at bedtime is preferred for maintenance therapy 1. Initial therapy may use divided doses if needed for tolerability, but consolidate to single daily dose for convenience and compliance 1. Research confirms plasma levels remain stable with once-daily dosing due to long half-life 8.
Special Populations
Elderly (>75 years): Start 10-25 mg morning, maximum 100 mg daily 3, 1. Note that elderly patients may show relative "resistance" to treatment even at adequate plasma levels 9, requiring careful monitoring and potentially longer trial periods.
Adolescents: Same dosing as elderly: 25-100 mg daily, maximum 150 mg in severe cases 1.
Drug Interactions
Critical interactions requiring dose adjustment or avoidance:
- MAOIs: Absolute contraindication; 14-day washout required 1
- Linezolid or IV methylene blue: Stop desipramine promptly if urgent treatment needed 1
- CYP2D6 inhibitors (paroxetine, fluoxetine): Can increase desipramine levels >400% 10. Sertraline has minimal interaction 10
- Other serotonergic drugs: Increased serotonin syndrome risk (triptans, tramadol, fentanyl, lithium, St. John's Wort) 1
Switching Antidepressants
When switching to desipramine from an MAOI: Wait 14 days after MAOI discontinuation 1.
When switching from desipramine to an MAOI: Wait 14 days after desipramine discontinuation 1.
Maintenance Treatment
After achieving remission, continue treatment for 4-9 months minimum 7. For patients with ≥2 prior episodes, longer duration therapy is beneficial 7. Use the lowest effective dose that maintains remission 1. Taper over 10-14 days when discontinuing to limit withdrawal symptoms 3.
Common Pitfalls
- Inadequate dosing: Many patients receive subtherapeutic doses; ensure plasma levels ≥115 ng/mL 4
- Premature discontinuation: Full trial requires 6-8 weeks 2
- Missing cardiac screening: ECG mandatory in patients >40 years 2
- Ignoring drug interactions: Particularly with CYP2D6 inhibitors 10
- Insufficient suicide monitoring: Weekly assessment critical in first month 1